# EDGAR Filing Document

**Accession Number:** 0001896212
**File Stem:** 0001641172-25-021793
**Filing Date:** 2025-7
**Character Count:** 23327
**Document Hash:** aac7eb21fbd253857297e5912bb37a53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-021793.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001641172-25-021793

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CONDUIT PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001896212
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 873272543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93313
- **FILM NUMBER:** 251173318

**BUSINESS ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103
- **BUSINESS PHONE:** (646) 491 9132

**MAIL ADDRESS:**
- **STREET 1:** 4851 TAMIAMI TRAIL NORTH
- **STREET 2:** SUITE 200
- **CITY:** NAPLES
- **STATE:** FL
- **ZIP:** 34103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Murphy Canyon Acquisition Corp.
- **DATE OF NAME CHANGE:** 20211130
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corvus Capital Ltd.
- **CENTRAL INDEX KEY:** 0001990829

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** WILLOW HOUSE, CRICKET SQUARE PO BOX 709
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1 - 1107
- **BUSINESS PHONE:** 44 7766 766766

**MAIL ADDRESS:**
- **STREET 1:** WILLOW HOUSE, CRICKET SQUARE PO BOX 709
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1 - 1107

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

**PURSUANT TO RULE 13d-1(k)**

Each of the undersigned acknowledge and agree that the foregoing Amendment No. 2 to Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to the Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

---

| | | |
|:---|:---|:---|
| Date: July 31, 2025 |  |  |
|  | Corvus Capital Ltd. | Corvus Capital Ltd. |
|  | By: | */s/ Andrew Regan* |
|  |  | Andrew Regan |
|  |  | Chief Executive Officer |

---

---

| | | |
|:---|:---|:---|
| Date: July 31, 2025 |  |  |
|  | Algo Holdings, Inc. | Algo Holdings, Inc. |
|  | By: | */s/ Alexander Lambert* |
|  |  | Alexander Lambert |
|  |  | Director |

---

---

| | | |
|:---|:---|:---|
| Date: July 31, 2025 |  |  |
|  | MANOIRA CORPORATION | MANOIRA CORPORATION |
|  | By: | */s/ Andrew Regan* |
|  |  | Andrew Regan |
|  |  | Director |

---

---

| | | |
|:---|:---|:---|
| Date: July 31, 2025 | | |
|  | Andrew Regan | Andrew Regan |
|  |  | */s/ Andrew Regan* |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Conduit Pharmaceuticals Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**20678X304**

*(CUSIP Number)*

**Andrew Regan**<br>Corvus Capital Ltd.<br>4851 Tamiami Trail North, Suite 200<br>Naples FL 34103<br>44 7766 766766

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/03/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **20678X304** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Corvus Capital Ltd.** | Name of reporting person<br>**Corvus Capital Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**174949.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**174949.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**174949.00** | Aggregate amount beneficially owned by each reporting person<br>**174949.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.0%** | Percent of class represented by amount in Row (11)<br>**6.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** On January 24, 2025, the Issuer effected a 1-for-100 reverse stock split (the "January Reverse Split") and, on May 15, 2025, subsequently effected a 1-for-15 reverse stock split (together with the January 2025 Reverse Split, the "Reverse Splits"). The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Splits.

| **CUSIP No.** | **20678X304** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Andrew Regan** | Name of reporting person<br>**Andrew Regan** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**44.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**174949.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**44.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**174949.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**174993.00** | Aggregate amount beneficially owned by each reporting person<br>**174993.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.0%** | Percent of class represented by amount in Row (11)<br>**6.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Splits.

| **CUSIP No.** | **20678X304** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Algo Holdings, Inc.** | Name of reporting person<br>**Algo Holdings, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**118.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**118.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**118.00** | Aggregate amount beneficially owned by each reporting person<br>**118.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Splits.

| **CUSIP No.** | **20678X304** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Manoira Corporation** | Name of reporting person<br>**Manoira Corporation** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**154799.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**154799.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**154799.00** | Aggregate amount beneficially owned by each reporting person<br>**154799.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Conduit Pharmaceuticals Inc.

**(c) Address of Issuer's Principal Executive Offices:**
4851 Tamiami Trail North, Suite 200, Naples, FL, 34103

This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") relating to the shares of common stock, par value $0.001 per share ("Common Stock"), of Conduit Pharmaceuticals Inc., a Delaware corporation (the "Issuer"), amends and supplements the Schedule 13D (the "Original Schedule 13D") originally filed by the Reporting Persons with the Securities and Exchange Commission (the "Commission") on September 29, 2023, as amended by Amendment No. 1 to the Original Schedule 13D, filed by the Reporting Persons with the Commission on September 19, 2024 ("Amendment No. 1" and, together with the Original Schedule 13D, the "Schedule 13D").

Except as specifically amended below, all other provisions of the Schedule 13D remain in effect. Capitalized terms used herein but not defined herein have the respective meanings ascribed to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

"Item 4. Purpose of Transaction." of the Schedule 13D is being amended and restated by this Amendment No. 2 as follows:

Algo, Corvus and Dr. Regan acquired the shares of Common Stock owned directly by each such Reporting Person in connection with the Merger contemplated by the Merger Agreement for investment purposes. The information contained in Item 3 of this Amendment No. 2 is incorporated herein by reference.

 In September 2023, in connection with the Merger, Corvus and Algo entered into a participation and inducement agreement (the "Inducement Agreement") with a third party investor in the Issuer, whereby Corvus and Algo agreed to provide certain payments to such investor in the event Corvus and Algo sold or pledged in a debt transaction any of the shares it was receiving in the Merger. In certain circumstances, such investor may have a right to cause Corvus to transfer certain of its shares to such investor.

On March 26, 2024, Algo pledged (such pledge, the "Algo Pledge") 14,378,695 shares of Common Stock directly owned by it, which constituted all of the shares of Common Stock held in its margin account at RBC Capital Markets, LLC ("RBC"), to RBC as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and RBC (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts owed by Corvus and Algo to the third party investor pursuant to the Inducement Agreement.

On June 14, 2024, Corvus transferred 1,100,000 shares of Common Stock directly owned by it to Algo for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024 (the "Transfer Request" and such transfer, the "Corvus Transfer").

On June 24, 2024, Corvus entered into a Guaranty of Account with RBC (the "Guaranty of Account") to guarantee Algo's remaining obligations under the Loan Agreement and in connection therewith pledged 30,048,454 shares of Common Stock directly owned by it, which constituted all of the shares of Common Stock held in Corvus's margin account at RBC, to RBC (such pledge, the "Corvus Pledge").

From July 3, 2024 to July 17, 2024, RBC sold a total of 15,301,068 shares of Common Stock from Algo's account at RBC pursuant to the terms and conditions of the Loan Agreement, as detailed on Schedule A attached hereto.

On June 3, 2025, Manoira entered into the Joint Development Agreement with the Issuer and agreed to fund all of the development activities of the collaboration and, in lieu of any further obligation for development costs, the Issuer issued 154,799 shares of Common Stock as an up-front consideration of $500,000.

The foregoing descriptions of the Loan Agreement, the Transfer Request, the Guaranty of Account and the Joint Development Agreement do not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement, the Transfer Request and the Guaranty of Account, which are filed as Exhibits 8, 9, 10 and 12, respectively, to the Schedule 13D and incorporated herein by reference.

Dr. Regan is the Chief Executive Officer of the Issuer and serves as a director on the Issuer's board of directors. Accordingly, Dr. Regan may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of the Schedule 13D. Except as otherwise described herein, the Reporting Persons currently have no plan(s) or proposal(s) that relate to, or would result in, any of the events or transactions described in Item 4(a) through (j) of the Schedule 13D, although each Reporting Person reserves the right, at any time and from time to time, to review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto. The Reporting Persons intend to review from time to time their investment in the Issuer and the Issuer's business affairs, financial position, performance and other investment considerations. The Reporting Persons may from time to time engage in discussions with the Issuer, its directors and officers, other stockholders of the Issuer and other persons on matters that relate to the management, operations, business, assets, capitalization, financial condition, strategic plans, governance and the future of the Issuer and/or its subsidiaries. Based upon such review and discussions, as well as general economic, market and industry conditions and prospects and the Reporting Persons' liquidity requirements and investment considerations, and subject to the limitations in the agreements described above, the Reporting Persons may consider additional courses of action, which may include, in the future, formulating plans or proposals regarding the Issuer and/or its subsidiaries, including possible future plans or proposals concerning events or transactions of the kind described in Item 4(a) through (j) of the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated by this Amendment No. 2 as follows:

(a)-(b) The percentage ownership of shares of Common Stock set forth in this Amendment No. 2 is based upon 2,925,862 shares of Common Stock outstanding as of July 21, 2025, as independently confirmed by the Issuer.

On January 24, 2025, the Issuer effected a 1-for-100 reverse stock split (the "January Reverse Split") and, on May 15, 2025, subsequently effected a 1-for-15 reverse stock split (together with the January 2025 Reverse Split, the "Reverse Splits"). The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Splits.

Corvus beneficially owns 174,949 shares of Common Stock, including 20,032 shares of Common Stock owned directly by Corvus, 118 shares of Common Stock owned directly by Algo, its wholly-owned subsidiary, and 154,799 shares of Common Stock owned directly by Manoira, of which Corvus is owner of 99% of its equity interests, which represents approximately 5.98% of the issued and outstanding shares of Common Stock as of July 21, 2025.

Dr. Regan beneficially owns 174,993 shares of Common Stock, including 44 shares of Common Stock held directly by Dr. Regan, 20,032 shares of Common Stock owned directly by Corvus, 118 shares of Common Stock owned directly by Algo and 154,799 shares of Common Stock owned directly by Manoira, which represents approximately 5.98% of the issued and outstanding shares of Common Stock as of July 21, 2025. Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly-owned subsidiary of Corvus. Dr. Regan is the sole director of Manoira, of which Corvus is the 99.0% owner of its equity interests. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus, Algo and Manoira. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Algo beneficially owns 118 shares of Common Stock, which represents approximately 0.00% of the issued and outstanding shares of Common Stock as of July 21, 2025.

Manoira beneficially owns 154,799 shares of Common Stock, which represents approximately 5.29% of the issued and outstanding shares of Common Stock as of July 21, 2025.

To the Reporting Persons' knowledge, the other individuals named in Item 2 above do not beneficially own any shares of Common Stock.

**(b)**
—

**(c)**
Except as set forth in Item 4 of this Amendment No. 2, none of the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the individuals named in Item 2 above, have engaged in any transaction with respect to the shares of Common Stock during the sixty (60) days prior to the trigger date for the filing of this Amendment No. 2.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

"Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer." of the Schedule 13D is being amended by this Amendment No. 2 to add the following:

 The disclosure in Item 4 hereof with respect to the Joint Development Agreement is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Corvus Capital Ltd.

**Signature:** /s/ Andrew Regan

**Name/Title:** Andrew Regan/Chief Executive Officer

**Date:** 07/31/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Andrew Regan

**Signature:** /s/ Andrew Regan

**Name/Title:** Andrew Regan

**Date:** 07/31/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Algo Holdings, Inc.

**Signature:** /s/ Alexander Lambert

**Name/Title:** Alexander Lambert/Director

**Date:** 07/31/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Manoira Corporation

**Signature:** /s/ Andrew Regan

**Name/Title:** Andrew Regan/Director

**Date:** 07/31/2025